

**Pharmacy Policy**

---

# Xpovio

**Policy Number:** 9.726

**Version Number:** 1.0

**Version Effective Date:** 9/1/2021

Product Applicability <input type="checkbox"/> <b>All Plan+ Products</b>	
<b>Well Sense Health Plan</b>	<b>Boston Medical Center HealthNet Plan</b>
<input type="checkbox"/> New Hampshire Medicaid	<input checked="" type="checkbox"/> MassHealth - MCO
	<input checked="" type="checkbox"/> MassHealth - ACO
	<input type="checkbox"/> Qualified Health Plans/ConnectorCare/Employer Choice Direct
	<input type="checkbox"/> Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

**Prior Authorization Policy**

---

**Products Affected:**

- **Xpovio (selinexor) 20mg Tablets**

The Plan may authorize coverage of the above products for members meeting the following criteria:

<b>Covered Use</b>	All FDA approved indications not otherwise excluded
<b>Exclusion Criteria</b>	None
<b>Required Medical Information</b>	<p><u>Multiple Myeloma:</u></p> <p>1. Member has diagnosis of relapsed or refractory Multiple Myeloma (RRMM); <b>AND</b></p>

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

	<p>2. Member has disease refractory to all of the following: at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody; <b>OR</b></p> <p><u>Diffuse Large B-Cell Lymphoma (DLBCL):</u></p> <p>1. Member has diagnosis of relapsed or refractory large B-cell lymphoma (DLBCL) (including DLBCL arising from follicular lymphoma) <b>AND</b></p> <p>2. Patient has received at least 2 lines of systemic therapy</p>
<b>Age Restriction</b>	Member is 18 years of age or older.
<b>Prescriber Restriction</b>	Prescribed by or in consultation with an oncologist.
<b>Coverage Duration</b>	12 months
<b>Quantity Limit</b>	None
<b>Other criteria</b>	<p>Reauthorization Criteria:</p> <p>1. Member has met initial criteria. <b>AND</b></p> <p>2. Member does not show evidence of progressive disease while on therapy.</p>

**Applicable coding:**

Code	Medication
N/A	

**Clinical Background Information and References**

1. Xpovio (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics Inc; April 2021
2. National Comprehensive Cancer Network. Diffuse Large B-Cell Lymphoma (Version 4.2021). [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf) . Accessed March 2021.
3. National Comprehensive Cancer Network. Multiple Myeloma (Version 7.2021). [https://www.nccn.org/professionals/physician\\_gls/pdf/myeloma.pdf](https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf) Accessed April 2021.
4. UpToDate. Selinexor: Drug information. Topic 121843 Version 62.0. Accessed March 2021.

<b>Original Approval Date</b>	<b>Original Effective Date</b>	<b>Policy Owner</b>	<b>Approved by</b>
-------------------------------	--------------------------------	---------------------	--------------------

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

5/13/2021	9/1/2021	Pharmacy Department	P&T Committee & DHHS
-----------	----------	---------------------	----------------------

### Policy Revisions History

Review Date	Summary of Revisions	Revision Effective Date	Approved by
5/13/2021	Policy created	9/1/2021	P&T Committee

### Next Review Date

5/2022

### Other Applicable Policies

### Reference to Applicable Laws and Regulations, If Any

### Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

\* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.